With Biktarvy patent cliff ahead, Gilead lays out a plan to keep the HIV crown with 7 launches through 2033

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching toward a 2033 patent cliff, the drugmaker at its HIV investor event laid out an analyst-lauded plan to extend its HIV dominance into the next decade and beyond.